Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Arrotex hails biosim boost

Posted 7 May 2021 AM

Following the launch of its specialist biosimilar portfolio - Arrotex Biologics - in February, the big generics business is already hailing the new approach a success.

In particular, it says that since the PBS listing of Humira biosims in April, their uptake has surpassed the switch rate achieved in the whole of the first year of etanercept biosimilar, Brenzys.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Could access probe be for nothing?
Significant industry participation but what outcome?
Approvals Action
Injectable antibiotic ticked
Fresenius Kabi adds to Gram-positive options